Concentration, Structure and Iron Saturation of Ferritins from Normal Human Lung and Lung Tumors with Graded Histopathology

Enzyme ◽  
1982 ◽  
Vol 27 (3) ◽  
pp. 189-198 ◽  
Author(s):  
Maria C. Linder ◽  
Kristine Wright ◽  
James Madara
1996 ◽  
Vol 44 (1) ◽  
pp. 3-12 ◽  
Author(s):  
L Saldise ◽  
A Martínez ◽  
L M Montuenga ◽  
A Treston ◽  
D R Springall ◽  
...  

C-terminal alpha-amidation is a post-translational modification necessary for the biological activity of many regulatory peptides produced in the respiratory tract. This modification is a two-step process catalyzed by two separate enzyme activities, both derived from the peptidyl-glycine alpha-amidating mono-oxygenase (PAM) precursor. The distribution of these two enzymes, peptidyl-glycine alpha-hydroxylating monoxygenase (PHM) and peptidyl-alpha-hydroxyglycine a amidating lyase (PAL), was studied in the normal lung and in lung tumors using immunocytochemical methods and in situ hybridization. In normal lung the enzymes were located in some cells of the airway epithelium and glands, the endothelium of blood vessels, some chondrocytes of the bronchial cartilage, the alveolar macrophages, smooth muscle cells, neurons of the intrinsic ganglia, and in myelinated nerves. A total of 24 lung tumors of seven different histological types were studied. All cases contained PAM-immunoreactive cells with various patterns of distribution. All immunoreactive cells were positive for the PHM antiserum but only some of them for the PAL antiserum. The distribution of PAM co-localizes with some other previously described amidated peptides, suggesting that amidation is an important physiological process taking place in the normal and malignant human lung tissue.


2021 ◽  
Vol 2 (1) ◽  
pp. 100267
Author(s):  
Stéphanie Corgnac ◽  
Yann Lecluse ◽  
Fathia Mami-chouaib
Keyword(s):  
T Cells ◽  

Lung Cancer ◽  
1988 ◽  
Vol 4 (3-4) ◽  
pp. 205-209 ◽  
Author(s):  
Jill M. Siegfried ◽  
Suzanne K. Hansen ◽  
Vickie Y. Lawrence ◽  
Sara E. Owens

Cancer ◽  
2001 ◽  
Vol 92 (6) ◽  
pp. 1402-1410 ◽  
Author(s):  
Randolph H. Hastings ◽  
Douglas W. Burton ◽  
Rick A. Quintana ◽  
Elana Biederman ◽  
Aneeta Gujral ◽  
...  

1996 ◽  
Vol 270 (1) ◽  
pp. L159-L163 ◽  
Author(s):  
M. J. Thomassen ◽  
J. M. Antal ◽  
B. P. Barna ◽  
L. T. Divis ◽  
D. P. Meeker ◽  
...  

The initial inflammatory event in the adult respiratory distress syndrome (ARDS) is followed by fibroproliferation and a cascade of fibroblast-derived mediators. Because lung fibroblasts may be exposed to surfactant as well as inflammatory cytokines during ARDS, we hypothesized that surfactant might modulate fibroblast activity. We previously demonstrated that surfactant inhibited production of inflammatory cytokines from endotoxin-stimulated human alveolar macrophages. In the current study the effects of surfactant on normal human lung fibroblast proliferative capacity and mediator production were examined. Both synthetic (Exosurf) and natural (Survanta) surfactant inhibited fibroblast [3H]thymidine incorporation. Examination of pre-S-phase events indicated stimulation of the immediate response gene, c-fos, and no effect on the G1/S cyclin, cyclin D1, suggesting that the surfactant block occurred elsewhere before S phase. The antioxidant N-acetyl-L-cysteine (NAC), like surfactant, inhibited [3H]thymidine incorporation. Furthermore, menadione, a generator of intracellular H2O2, stimulated fibroblast [3H]thymidine incorporation, and this was inhibited by surfactant. Interleukin-1 (IL-1)-stimulated secretion of the inflammatory mediators, IL-6 and prostaglandin E2, was also inhibited by surfactant. These data suggest that surfactant may modify lung fibroblast participation in ARDS sequelae by downregulating DNA synthesis and secondary inflammatory mediator production.


1994 ◽  
Vol 9 (2) ◽  
pp. 105-109 ◽  
Author(s):  
Martin B. Reichel ◽  
Hiroko Ohgaki ◽  
Iver Petersen ◽  
Paul Kleihues
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document